Our generous friends at Panda Express will double your impact and match donations - up to $500,000 - through Dec. 31. Make your tax-deductible gift now.
Phase 2 Study of Omalizumab in Oral Peanut Desensitization (PRROTECT)
Official Title:
Phase 2 Study of Omalizumab in Oral Peanut Desensitization (PRROTECT)
The investigators will perform a double blind, placebo controlled clinical trial with Xolair (omalizumab) at four centers to safely and rapidly desensitize patients with severe peanut allergy. The investigators will determine if pretreatment with anti-IgE mAb (Xolair/omalizumab) can greatly reduce allergic reactions and allow for faster and safer desensitization
Our generous friends at Panda Express will double your impact and match donations - up to $500,000 - through Dec. 31. Make your tax-deductible gift now.